Ken Griffin Achilles Therapeutics PLC Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.75 - $1.25 $32,701 - $54,502	-43,602 Reduced 41.53%	61,391 $50,000
Q1 2024 May 15, 2024	SELL	$0.82 - $1.57 $2,838 - $5,433	-3,461 Reduced 3.19%	104,993 $131,000
Q4 2023 Feb 14, 2024	BUY	$0.78 - $0.96 $39,645 - $48,794	50,828 Added 88.2%	108,454 $96,000
Q3 2023 Nov 14, 2023	SELL	$0.84 - $1.11 $7,742 - $10,230	-9,217 Reduced 13.79%	57,626 $52,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.09 $330 - $439	-403 Reduced 0.6%	66,843 $63,000
Q1 2023 May 15, 2023	BUY	$0.84 - $1.26 $35,491 - $53,237	42,252 Added 169.05%	67,246 $64,000
Q4 2022 Feb 14, 2023	BUY	$0.79 - $2.39 $19,745 - $59,735	24,994 New	24,994 $22,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $18,533 - $28,746	9,456 Added 52.5%	27,468 $69,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.23 $107,926 - $201,590	-38,545 Reduced 68.15%	18,012 $53,000
Q4 2021 Feb 14, 2022	BUY	$4.22 - $8.86 $73,022 - $153,313	17,304 Added 44.08%	56,557 $283,000
Q1 2021 May 17, 2021	BUY	$16.55 - $16.55 $649,637 - $649,637	39,253 New	39,253 $650,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $42M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.